Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maridebart cafraglutide versus placebo in adults with obstructive sleep apnea on positive airway pressure therapy and overweight or obesity
2025-522703-14-00Phase 3Authorised
- Sponsor
- Amgen
- Start
- Feb 2026
- Modality
- Peptide-Protein Conjugates → Peptide Conjugates → Peptides, Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Modified Peptides → Peptides
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in obstructive sleep apnea hypopnea syndrome (OSAHS) comparing Maridebart cafraglutide with Placebo (2 arms). Primary endpoint: Change in apnea-hypopnea index from baseline at week 52. Planned start Feb 2026; status: authorised.
02
Drugs
maridebart cafraglutide
03
Conditions
obstructive sleep apnea hypopnea syndrome (OSAHS)
Beyond the preview
Go deeper on 2025-522703-14-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522703-14-00.